• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products
You are here: Product Lines > Chemokines & Cytokines > Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products
Toolbar - View Selection
 
Items 10 of 10
ALX-270-448 Revised 24-Jul-06
ALK5 Inhibitor I
Add to Clipboard
SYNONYMS TGF-β RI Kinase Inhibitor I
3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-448-M001   1 mg 30.00 USD Add To Cart
ALX-270-448-M005   5 mg 90.00 USD Add To Cart
Product Specification
FORMULA: C17H12N4
MW: 272.3
PURITY: ≥97% (1H-NMR)
APPEARANCE: Yellow to brown solid.
SOLUBILITY: Soluble in DMSO or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for 2 years after receipt when stored at -20°C. Stock solutions are stable for up to 3 months when stored at -20°C.
HANDLING: Protect from light.
HAZARD: MAY BE CARCINOGENIC. HARMFUL.

Product Description

Cell permeable, potent, selective and ATP-competitive inhibitor of TGF-β RI kinase (IC50=51nM). Displays ~15-fold greater selectivity over p38α MAPK (IC50=740nM). Inhibits TGF-β-dependent cellular growth (IC50=89nM in NIH 3T3 mouse fibroblasts) and transcription activation (IC50=47nM in mink lung cells).
Product Specific Literature References
Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain: J.S. Sawyer, et al.; J. Med. Chem. 46, 3953 (2003) Abstract
Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI): J. Singh, et al.; Bioorg. Med. Chem. Lett. 13, 4355 (2003) Abstract
Further Categories Containing This Product:
MAPK Pathway Inhibitors
 
 
ALX-270-445 Revised 20-Jul-06
ALK5 Inhibitor II
Add to Clipboard
SYNONYMS TGF-β RI Kinase Inhibitor II
2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-445-M001   1 mg 60.00 USD Add To Cart
ALX-270-445-M005   5 mg 240.00 USD Add To Cart
Product Specification
FORMULA: C17H13N5
MW: 287.3
PURITY: ≥97% (1H-NMR)
APPEARANCE: Yellow solid.
SOLUBILITY: 5mg/ml soluble in DMSO or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for 2 years after receipt when stored at -20°C. Stock solutions are stable for up to 6 months when stored at -20°C.
HANDLING: Protect from light.

Product Description
Cell permeable, potent, selective and ATP-competitive inhibitor of TGF-β RI kinase (IC50=23nM, 4nM and 18nM for binding, auto-phosphorylation and cellular assay in HepG2 cells of TGF-β RI kinase, respectively). Minimally affects a panel of 9 closely related kinases including p38 MAPK (IC50>16µM).
Product Specific Literature References
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors: F. Gellibert, et al.; J. Med. Chem. 47, 4494 (2004) Abstract
Further Categories Containing This Product:
MAPK Pathway Inhibitors
 
 
APO-54N-032 Revised 18-Jun-08
ILEI (human) Detection Set [For ELISA Application]
Add to Clipboard
SYNONYMS Interleukin-like EMT Inducer (human) Detection Set [For ELISA Application]
FAM3C (human) Detection Set [For ELISA Application]
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Chemokines & Cytokines Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
APO-54N-032-KI01   1 Set 630.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
SENSITIVITY: 200 pg/ml (range 0 to 20 ng/ml).
QUANTITY: For 5x96 wells.
KIT/SET CONTAINS: 1 vial Standard (lyophilized) (STD).
1 vial Coating Antibody (COAT).
1 vial Detection Antibody (DET).
APPLICATION: For the quantitative determination of human ILEI from biological fluids (serum, plasma and cell culture supernatant).
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
General Information
In 2006, T. Waerner, et al. characterized ILEI as a key player in both epithelial to mesenchymal transition and late-stage carcinoma progression. EMT is a process that involves changes in gene expression, cytoskeleton organization, cell adhesion, and extracellular matrix composition. This process is important during tissue formation and organogenesis, but also during cancer progression, metastasis and chronic inflammation. ILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link Q92520: FAM3C (human)
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
Cloning, expression, and initial characterization of a novel cytokine-like gene family: Y. Zhu, et al.; Genomics 80, 144 (2002) Abstract
ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells: T. Waerner, et al.; Cancer Cell 10, 227 (2006) Abstract
Further Categories Containing This Product:
Cancer Other Products • ELISA Sets • Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products
 
 
ALX-522-137 Revised 18-Jun-08 New product
ILEI (human) (recombinant)
Add to Clipboard
SYNONYMS Interleukin-like EMT Inducer (human) (recombinant)
FAM3C (human) (recombinant)
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Chemokines & Cytokines Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-522-137-C010   10 µg 360.00 USD Add To Cart
Product Specification
MW: ~25kDa
SOURCE/HOST: Produced in CHO cells. Human ILEI (interleukin-like EMT inducer) (aa 25-227) is fused at the C-terminus to a FLAG®-tag
CONCENTRATION: 0.1mg/ml after reconstitution.
PURITY: ≥95% (SDS-PAGE)
FORMULATION: Lyophilized. Contains PBS.
ENDOTOXIN CONTENT: <0.1EU/µg purified protein (LAL test; Bio Whittaker).
RECONSTITUTION: Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 6 months after receipt when stored at -20°C.
HANDLING: After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
General Information
In 2006, T. Waerner, et al. characterized ILEI as a key player in both epithelial to mesenchymal transition and late-stage carcinoma progression. EMT is a process that involves changes in gene expression, cytoskeleton organization, cell adhesion, and extracellular matrix composition. This process is important during tissue formation and organogenesis, but also during cancer progression, metastasis and chronic inflammation. ILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link Q92520: FAM3C (human)

FLAG is a registered trademark of Sigma-Aldrich Co.
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
Cloning, expression, and initial characterization of a novel cytokine-like gene family: Y. Zhu, et al.; Genomics 80, 144 (2002) Abstract
ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells: T. Waerner, et al.; Cancer Cell 10, 227 (2006) Abstract
Further Categories Containing This Product:
Recombinant Proteins / Fusion Proteins • Cancer Other Products • Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products
 
 
ALX-522-119 Revised 18-Jun-08
ILEI (mouse) (recombinant)
Add to Clipboard
SYNONYMS Interleukin-like EMT Inducer (mouse) (recombinant)
FAM3C (mouse) (recombinant)
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Chemokines & Cytokines Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-522-119-C010   10 µg 360.00 USD Add To Cart
Product Specification
MW: ~25kDa
SOURCE/HOST: Produced in HEK 293 cells. Mouse ILEI (interleukin-like EMT inducer) (aa 25-227) is fused at the C-terminus to a FLAG®-tag
CONCENTRATION: 0.1mg/ml after reconstitution.
PURITY: ≥95% (SDS-PAGE)
FORMULATION: Lyophilized. Contains PBS.
ENDOTOXIN CONTENT: <0.1EU/µg purified protein (LAL test; Bio Whittaker).
RECONSTITUTION: Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 6 months after receipt when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
General Information
In 2006, T. Waerner, et al. characterized ILEI as a key player in both epithelial to mesenchymal transition and late-stage carcinoma progression. EMT is a process that involves changes in gene expression, cytoskeleton organization, cell adhesion, and extracellular matrix composition. This process is important during tissue formation and organogenesis, but also during cancer progression, metastasis and chronic inflammation. ILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link Q91VU0: FAM3C (mouse)

FLAG is a registered trademark of Sigma-Aldrich Co.
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
Cloning, expression, and initial characterization of a novel cytokine-like gene family: Y. Zhu, et al.; Genomics 80, 144 (2002) Abstract
ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells: T. Waerner, et al.; Cancer Cell 10, 227 (2006) Abstract
Further Categories Containing This Product:
Recombinant Proteins / Fusion Proteins • Cancer Other Products • Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products
 
 
ALX-804-857 Revised 18-Jun-08
Monoclonal Antibody to ILEI (Delphy-1)
Add to Clipboard
SYNONYMS anti-Interleukin-like EMT Inducer MAb (Delphy-1)
anti-FAM3C MAb (Delphy-1)
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Chemokines & Cytokines Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-804-857-C100   100 µg 360.00 USD Add To Cart
ALX-804-857B-C100 Biotin 100 µg 395.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
CLONE: Delphy-1
ISOTYPE: Mouse IgG2a
SOURCE/HOST: Purified from concentrated hybridoma tissue culture supernatant.
CONCENTRATION: 1mg/ml
PURITY: ≥95% (SDS-PAGE)
PURITY DETAIL: Protein G-affinity purified.
FORMULATION: Liquid. In PBS containing 0.02% sodium azide.
IMMUNOGEN: Recombinant human ILEI (aa 42-227).
SPECIFICITY: Recognizes human and mouse ILEI.
APPLICATION: ELISA
Immunoprecipitation (1:100)
Western Blot (1:1’000)
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
USE/STABILITY: Stable for at least 1 year after receipt when stored as recommended.
HANDLING: For long term storage keep unconjugated antibody at -20°C. Avoid freeze/thaw cycles. Keep ATTO, Biotin- and FITC-conjugated formats at +4°C. Do not freeze. Protect from light.
General Information
In 2006, T. Waerner, et al. characterized ILEI as a key player in both epithelial to mesenchymal transition and late-stage carcinoma progression. EMT is a process that involves changes in gene expression, cytoskeleton organization, cell adhesion, and extracellular matrix composition. This process is important during tissue formation and organogenesis, but also during cancer progression, metastasis and chronic inflammation. ILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
Cloning, expression, and initial characterization of a novel cytokine-like gene family: Y. Zhu, et al.; Genomics 80, 144 (2002) Abstract
ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells: T. Waerner, et al.; Cancer Cell 10, 227 (2006) Abstract
Further Categories Containing This Product:
Cancer Other Products • Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products • Monoclonal Antibodies
 
 
ALX-804-858 Revised 18-Jun-08
Monoclonal Antibody to ILEI (Delphy-2)
Add to Clipboard
SYNONYMS anti-Interleukin-like EMT Inducer MAb (Delphy-2)
anti-FAM3C MAb (Delphy-2)
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Chemokines & Cytokines Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-804-858-C100   100 µg 360.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
CLONE: Delphy-2
ISOTYPE: Mouse IgM
SOURCE/HOST: Purified from concentrated hybridoma tissue culture supernatant.
CONCENTRATION: 1mg/ml
PURITY: ≥95% (SDS-PAGE)
PURITY DETAIL: Protein G-affinity purified.
FORMULATION: Liquid. In PBS containing 0.02% sodium azide.
IMMUNOGEN: Recombinant human ILEI (aa 42-227).
SPECIFICITY: Recognizes human and mouse ILEI.
APPLICATION: ELISA
Western Blot (1:1'000)
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 1 year after receipt when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
General Information
In 2006, T. Waerner, et al. characterized ILEI as a key player in both epithelial to mesenchymal transition and late-stage carcinoma progression. EMT is a process that involves changes in gene expression, cytoskeleton organization, cell adhesion, and extracellular matrix composition. This process is important during tissue formation and organogenesis, but also during cancer progression, metastasis and chronic inflammation. ILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
Cloning, expression, and initial characterization of a novel cytokine-like gene family: Y. Zhu, et al.; Genomics 80, 144 (2002) Abstract
ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells: T. Waerner, et al.; Cancer Cell 10, 227 (2006) Abstract
Further Categories Containing This Product:
Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products • Monoclonal Antibodies
 
 
ALX-804-871 Revised 14-Oct-08 New product
Monoclonal Antibody to TGF-βRIII (human) (Jack-1)
Add to Clipboard
SYNONYMS anti-TGFR-3 (human) MAb (Jack-1)
anti-Transforming Growth Factor β Receptor III (human) MAb (Jack-1)
anti-Betaglycan (human) MAb (Jack-1)
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-804-871-C100   100 µg 380.00 USD Add To Cart
Product Specification
CLONE: Jack-1
ISOTYPE: Mouse IgG2b
SOURCE/HOST: Purified from concentrated hybridoma tissue culture supernatant.
CONCENTRATION: 1mg/ml
PURITY: ≥95% (SDS-PAGE)
PURITY DETAIL: Protein G-affinity purified.
FORMULATION: Liquid. In PBS containing 0.02% sodium azide.
IMMUNOGEN: Recombinant human TGFβRIII cytoplasmic domain (aa 809-850).
SPECIFICITY: Recognizes human TGFβRIII.
APPLICATION: Immunoprecipitation (1:200)
Western Blot (1:1‘000)
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 1 year after receipt when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
General Information
TGF-β receptor III (TGF-βRIII; betaglycan) is an ubiquitously expressed transmembrane proteoglycan TGF-β co-receptor [1] that regulates TGF-β signaling by increasing the binding of TGF-β to the TGF-β receptor. (Note: The TGF-β receptor III is a co-receptor of TGF-β receptor, composed of subunit I and II; TGF-β receptor III increases the binding of TGF-β to the subunit II. In this way it can regulate the signaling.) TGF-β receptor III expression is lost in many human breast and prostate cancers and correlates with the resistance to the tumor suppressor effects of TGF-β  [2] . The overexpression of TGF-β receptor III in breast cancer cells suppresses their tumorigenicity in an animal model [3].
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
[1] Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta: N. Hempel, et al.; Carcinogenesis 29, 905 (2008) Abstract
[2] The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer: R.S. Turley, et al.; Cancer Res. 67, 1090 (2007) Abstract; Full Text
[3] The type III TGF-beta receptor suppresses breast cancer progression: M. Dong, et al.; J. Clin. Invest. 117, 206 (2006) Abstract; Full Text
Further Categories Containing This Product:
Monoclonal Antibodies
 
 
ALX-210-948 Revised 18-Jun-08
Polyclonal Antibody to ILEI (AT123)
Add to Clipboard
SYNONYMS anti-Interleukin-like EMT Inducer PAb (AT123)
anti-FAM3C PAb (AT123)
PRODUCT LINE Chemokines & Cytokines
PRODUCT CATEGORY Chemokines & Cytokines Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-210-948-C100   100 µg 350.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
SOURCE/HOST: From rabbit.
CONCENTRATION: 1mg/ml
PURITY DETAIL: Protein A-affinity purified.
FORMULATION: Liquid. In PBS containing 0.02% sodium azide.
IMMUNOGEN: Recombinant mouse ILEI (aa 25-227) (Prod. No. ALX-522-119).
SPECIFICITY: Recognizes human and mouse ILEI.
APPLICATION: Immunoprecipitation (1:200)
Western Blot (1:1’000)
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 1 year after receipt when stored at -20°C.
HANDLING: After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
General Information
In 2006, T. Waerner, et al. characterized ILEI as a key player in both epithelial to mesenchymal transition and late-stage carcinoma progression. EMT is a process that involves changes in gene expression, cytoskeleton organization, cell adhesion, and extracellular matrix composition. This process is important during tissue formation and organogenesis, but also during cancer progression, metastasis and chronic inflammation. ILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
Cloning, expression, and initial characterization of a novel cytokine-like gene family: Y. Zhu; Genomics 80, 144 (2002) Abstract
ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells: T. Waerner, et al.; Cancer Cell 10, 227 (2006) Abstract
Further Categories Containing This Product:
Transforming Growth Factor beta [TGFbeta] & Receptors / Related Products • Cancer Other Products • Polyclonal Antibodies
 
 
ALX-200-088 Revised 26-Mar-08
TGF-β1 (human)
Add to Clipboard
PRODUCT LINE Chem